Table 1. Properties of NB-LUMABS Sensors^a.

Target	Sensor name	SB1 affinityb	SB2 affinityb	Cy3 position	DR (%)	Sensor Kd
Anti-HIV1-p17	HIV-NB-LUMABS-1	Kd = 190 μM	Kd = 2.5 μM	before SB2	218 ± 12	10.0 ± 0.5 pM
	HIV-NB-LUMABS-2	Kd = 190 μM	Kd = 2.5 μM	after SB2	177 ± 4	13.7 ± 1.3 pM
	HIV-NB-LUMABS-3	Kd = 190 μM	Kd = 2.5 μM	before and after SB2	182 ± 18	12.1 ± 0.6 pM
	HIV-NB-LUMABS-4	Kd = 190 μM	Kd = 0.18 μM	before SB2	138 ± 5	14.2 ± 4.7 pM
	HIV-NB-LUMABS-5	Kd = 190 μM	Kd = 190 μM	before SB2	252 ± 15	11.7 ± 3.7 pM
	HIV-NB-LUMABS-6	Kd = 2.5 μM	Kd = 2.5 μM	before SB2	160 ± 3	15.2 ± 1.0 pM
	HIV-NB-LUMABS-7	Kd = 2.5 μM	Kd = 0.18 μM	before SB2	493 ± 13	11.8 ± 0.5 pM
Cetuximab	CTX-NB-LUMABS-1c	Kd = 190 μM	Kd = 2.5 μM	before SB2	233 ± 12	34.7 ± 3.7 nM
	CTX-NB-LUMABS-2c	Kd = 190 μM	Kd = 2.5 μM	after SB2	110 ± 3	20.7 ± 3.4 nM
	CTX-NB-LUMABS-3d	Kd = 190 μM	Kd = 2.5 μM	before SB2	88 ± 2	189 ± 16 nM

^aThe measurements were performed in PBS buffer (pH 7.4, 1 mg/mL BSA) with sensor concentration of 1 pM for anti-HIV-p17 and 100 pM for cetuximab.

^bSee ref (22).

^cMeditope sequence CVFDLGTRRLRC (monovalent K_d = 61 nM).

^dMeditope sequence CQFDLSTRRLKC (monovalent K_d = 270 nM).